Bristol-Myers Squibb Co (BMY) Stock Price Today—Real Time Charts and Quotes

Q: What's the stock price of Bristol-Myers Squibb Co (BMY) today?

Bristol-Myers Squibb Co (BMY) is currently trading at $59.48, with a 24h change of -0.4%. The 52-week trading range is $57–$60.25.

Q: What are the 52-week high and low prices for Bristol-Myers Squibb Co (BMY)?

BMY has a 52-week high of $60.25 and a 52-week low of $57, with the current price at $59.48.

Q: What is the price-to-earnings (P/E) ratio of Bristol-Myers Squibb Co (BMY)? What does it indicate?

The current P/E ratio (TTM) of BMY is 15.609179072735005, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Drug Manufacturers - General industry for a better context.

Q: What is the market cap of Bristol-Myers Squibb Co (BMY)?

Bristol-Myers Squibb Co (BMY) currently has a market cap of approximately $121.42B.

Q: What is the most recent quarterly earnings per share (EPS) for Bristol-Myers Squibb Co (BMY)?

Bristol-Myers Squibb Co (BMY)'s diluted earnings per share (Diluted EPS) is 3.5600493464434497. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell Bristol-Myers Squibb Co (BMY) now?

As of now, BMY is trading at $59.48, with a P/E ratio of 15.609179072735005 and a diluted EPS of 3.5600493464434497. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering Bristol-Myers Squibb Co's financial reports, the outlook of the Drug Manufacturers - General sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of Bristol-Myers Squibb Co (BMY)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Drug Manufacturers - General sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy Bristol-Myers Squibb Co (BMY) stock?

You can buy Bristol-Myers Squibb Co (BMY) through Gate. Sign up for a Gate account and complete identity verification, then go to the Bristol-Myers Squibb Co trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$59,48

-$0,25(-0,41 %)

*Data last updated: 2026-05-23 08:04 (UTC+8)

As of 2026-05-23 08:04, Bristol-Myers Squibb Co (BMY) is priced at $59,48, with a total market cap of $121,42B, a P/E ratio of 15,60, and a dividend yield of 4,20 %. Today, the stock price fluctuated between $59,00 and $60,25. The current price is 0,81 % above the day's low and 1,27 % below the day's high, with a trading volume of 6,67M. Over the past 52 weeks, BMY has traded between $57,00 to $60,25, and the current price is -1,27 % away from the 52-week high.

BMY Key Stats

Yesterday's Close$59,55

Market Cap$121,42B

Volumen6,67M

P/E Ratio15,60

Dividend Yield (TTM)4,20 %

Dividend Amount$0,63

Diluted EPS (TTM)3,56

Net Income (FY)$7,05B

Revenue (FY)$48,19B

Earnings Date2026-10-29

EPS Estimate1,61

Revenue Estimate$12,02B

Shares Outstanding2,03B

Beta (1Y)0.259

Ex-Dividend Date2026-04-02

Dividend Payment Date2026-05-01

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

SectorHealthcare

IndustryDrug Manufacturers - General

CEOChristopher S. Boerner

HeadquartersPrinceton,NJ,US

Official Websitehttps://www.bms.com

Employees (FY)32,50K

Average Revenue (1Y)$1,48M

Net Income per Employee$217,01K

Erfahren Sie mehr über Bristol-Myers Squibb Co (BMY)

Gate Learn Articles

Die prächtige Blase und die verlorene Wahrheit der Promi-TokenDer HAWK-Token sollte ursprünglich finanzielle Unterstützung für Haustierwohltätigkeiten bieten, aber sein rasanter Anstieg und Absturz nach dem Listing enthüllten die üblichen Betrugsmuster auf dem Kryptowährungsmarkt. Hailey Welchs Token sah seinen Marktwert in nur drei Stunden auf 490 Millionen Dollar steigen, nur um kurz darauf um 91% zu fallen, was zu erheblichen Verlusten für viele Anleger führte. Die zugrunde liegenden Probleme der Token-Konzentrationsverteilung, frühe 'Sniping'-Gewinne und die erheblichen Risiken von Promi-Tokens machen dieses Ereignis zu einem weiteren typischen Fall im Bereich der Kryptowährungen.2025-02-17

Bristol-Myers Squibb Co (BMY) FAQ

What's the stock price of Bristol-Myers Squibb Co (BMY) today?

Bristol-Myers Squibb Co (BMY) is currently trading at $59,48, with a 24h change of -0,41 %. The 52-week trading range is $57,00–$60,25.

What are the 52-week high and low prices for Bristol-Myers Squibb Co (BMY)?

What is the price-to-earnings (P/E) ratio of Bristol-Myers Squibb Co (BMY)? What does it indicate?

What is the market cap of Bristol-Myers Squibb Co (BMY)?

What is the most recent quarterly earnings per share (EPS) for Bristol-Myers Squibb Co (BMY)?

Should you buy or sell Bristol-Myers Squibb Co (BMY) now?

What factors can affect the stock price of Bristol-Myers Squibb Co (BMY)?

How to buy Bristol-Myers Squibb Co (BMY) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.